NCT00137436 - Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

May 31, 2008

Study Completion Date

March 31, 2010

Conditions

Prostatic Neoplasms

Interventions

DRUG

Docetaxel

Docetaxel Phase 1 - escalating doses (60 and 75 mg/m2), intravenous therapy (IV), administered every 3 weeks. Phase 2 - Phase 1 optimal combination dose (75 mg/m2, IV, every 3 weeks).

DRUG

Prednisone

Prednisone Phase1/2 - 5 mg twice a day (BID), oral.

DRUG

SU011248

SU011248 Phase 1 - escalating doses (12.5, 37.5, and 50 mg), oral, administered on a 2-weeks on, 1-week off daily regimen (Schedule 2/1). Phase 2 - Phase 1 optimal combination dose (37.5 mg/day, oral, Schedule 2/1).

Trial Locations (24)

27710

Pfizer Investigational Site, Durham

29572

Pfizer Investigational Site, Myrtle Beach

37043

Pfizer Investigational Site, Clarksville

37066

Pfizer Investigational Site, Gallarin

37067

Pfizer Investigational Site, Franklin

37076

Pfizer Investigational Site, Hermitage

37087

Pfizer Investigational Site, Lebanon

37130

Pfizer Investigational Site, Murfreesboro

37166

Pfizer Investigational Site, Smithville

37167

Pfizer Investigational Site, Smyrna

37203

Pfizer Investigational Site, Nashville

37205

Pfizer Investigational Site, Nashville

37207

Pfizer Investigational Site, Nashville

37211

Pfizer Investigational Site, Nashville

37388

Pfizer Investigational Site, Tullahoma

46321

Pfizer Investigational Site, Munster

46342

Pfizer Investigational Site, Hobart

53792

Pfizer Investigational Site, Madison

60426

Pfizer Investigational Site, Harvey

60477

Pfizer Investigational Site, Tinley Park

75246

Pfizer Investigational Site, Dallas

77030

Pfizer Investigational Site, Houston

97239

Pfizer Investigational Site, Portland

97239-3098

Pfizer Investigational Site, Portland